Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers October 22, 2017
Pharmacy Choice - Pharmaceutical News - Analyst Activity HC Wainwright Lowers Its Price Target On Aurinia Pharmaceuticals (NASDAQ:AUPH) to $10.00 - October 22, 2017

Pharmacy News Article

 5/19/17 - Analyst Activity HC Wainwright Lowers Its Price Target On Aurinia Pharmaceuticals (NASDAQ:AUPH) to $10.00

Analyst Ratings For Aurinia Pharmaceuticals (NASDAQ:AUPH)

Today, HC Wainwright lowered its price target on Aurinia Pharmaceuticals (NASDAQ:AUPH) to $10.00 per share.

There are 7 buy ratings on the stock.

The current consensus rating on Aurinia Pharmaceuticals (NASDAQ:AUPH) is Buy (Score: 3.00) with a consensus target price of $10.67 per share, a potential 48.35% upside.

Some recent analyst ratings include

  • 4/21/2017-Cantor Fitzgerald Reiterated Rating of Buy.
  • 4/11/2017-FBR & Co Reiterated Rating of Outperform.
  • 11/4/2016-Bloom Burton Reiterated Rating of Buy.
  • 11/2/2016-Mackie Reiterated Rating of Buy.

Dividend information for Aurinia Pharmaceuticals (NASDAQ:AUPH)

.

    About Aurinia Pharmaceuticals (NASDAQ:AUPH)
    Aurinia Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company's primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN. Voclosporin is an oral drug, administered twice daily. It is structurally similar to cyclosporine A (CsA), but is chemically modified on the amino acid-1 residue. It has completed two Phase III clinical studies in patients with moderate to severe psoriasis. It has completed Phase IIb clinical trial, which is a randomized, controlled, double-blind study comparing the efficacy of voclosporin as a component of multi-targeted therapy against placebo in achieving remission in patients with active LN.

    Recent Trading Activity for Aurinia Pharmaceuticals (NASDAQ:AUPH)
    Shares of Aurinia Pharmaceuticals closed the previous trading session at 7.19 up +0.13 1.84% with 1,812,468 shares trading hands.

    The post Analyst Activity HC Wainwright Lowers Its Price Target On Aurinia Pharmaceuticals (NASDAQ:AUPH) to $10.00 appeared first on Market Exclusive.



© Market Exclusive 2017

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
Oct 23: Vitamin D Primer for Pharmacy Professionals
Oct 24: Metabolic Syndrome: The Heart of Any Wellness Practice
Oct 25: Dispensing Controlled Substances in Today’s Pharmacy
Oct 26: Management of Schizophrenia & Acute Agitation
Oct 27: Influenza 2017-2018: An Update on Prevention and Treatment
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415